Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00407199 · ClinicalTrials.gov registry record · Phase 4
The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment
A Phase 4 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT00407199 is a Phase 4 study that has completed, run by University of Minnesota. The registered enrollment target is 20 participants.
The verdict
NCT00407199, a Phase 4 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a pilot study that will focus on the collection of preliminary data to determine the efficacy of quetiapine for individuals with social phobia. We hypothesize that individuals will react with less self-reported anxiety and physiological reactivity in the drug condition than in the placebo condition. If true, this would constitute a strong signal for a significant treatment effect for quetiapine in social phobia. A positive treatment effect in this study would provide rationale for further investigation of the efficacy of quetiapine for cue reactivity for individuals with social phobia. Further study would include increased sample size in order to obtain statistical power and replication of findings. We will utilize the IR formulation of quetiapine.
Interventions
- DRUG quetiapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-12 |
| Est. Completion | 2007-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00407199
The ClinicalTrials.gov registry entry for NCT00407199 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which quetiapine is the first listed.
NCT00407199 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00407199 about?
NCT00407199 is a clinical study titled "The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment". This is a pilot study that will focus on the collection of preliminary data to determine the efficacy of quetiapine for individuals with social phobia. We hypothesize that individuals will react with less self-reported anxiety and physiological reactivity in the drug condition than in the placebo co...
What is the current status of trial NCT00407199?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2006-12. Estimated completion is 2007-09.
What interventions are being tested in trial NCT00407199?
The interventions under investigation include: quetiapine (DRUG).
Who is sponsoring clinical trial NCT00407199?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.